New Risk • Jan 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended April 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$358k free cash flow). Share price has been highly volatile over the past 3 months (53% average weekly change). Market cap is less than US$10m (CA$3.28m market cap, or US$2.45m). Minor Risks Latest financial reports are more than 6 months old (reported April 2023 fiscal period end). Revenue is less than US$5m (CA$2.2m revenue, or US$1.7m). Announcement • Jan 12
THC Biomed Intl Ltd. to Report Q1, 2024 Results on Feb 05, 2024 THC Biomed Intl Ltd. announced that they will report Q1, 2024 results on Feb 05, 2024 Announcement • Dec 09
THC Biomed Intl Ltd. Introduces Always Hi New Brand Catering to Maturing Cannabis Consumer Trends THC BioMed Intl Ltd. announced the launch of its latest brand, Always Hi TM, signaling a significant step forward in meeting the evolving needs of cannabis consumers. This new development showcases THC BioMed's commitment to innovation and addressing the dynamic preferences within the cannabis market. As the landscape of cannabis consumption continues to evolve, THC Biomed has meticulously crafted a diverse range of products under the Always Hi brand. These products are strategically designed to resonate with the maturing cannabis consumer trends, offering a fusion of quality, reliability, and heightened experiences. The newly developed range under the Always Hi brand encompasses an array of innovative offerings aimed at providing an enhanced and tailored experience for consumers seeking premium cannabis products. THC BioMed's commitment to quality assurance and meticulous product development ensures that each item delivers on the promise of excellence. The Always Hi new product line includes the following: Live rosin beverage shots; Ice Bubble Hash Beverage shot; Live Rosin Gummies and Edibles; Ice Bubble Hash Gummies and Edibles; Dragons' Lettuce line of new Innovative pre rolls; Stoned Freezable beverages. The launch of Always Hi signifies a pivotal moment for THC Biomed, marking the Company's dedication to continuous evolution and expansion within the cannabis market. Announcement • Jul 06
Thc Biomed Intl Ltd. Launches New Summer Cannabis Product: Thc Kiss Strawberry Tangerine Gummies THC BioMed Intl Ltd. announced the release of its summer product line, featuring the THC Kiss Strawberry Tangerine Gummies with 10% THC. The launch of these full-spectrum cannabis gummies represents the Company's commitment to product innovation and diversification. The company continue to work diligently to improve shareholder value and attract investor interest in the rapidly evolving cannabis market. The THC Kiss Strawberry Tangerine Gummies are full-spectrum cannabis products, made with the purest ingredients, promising consumers a superior experience. This product launch underlines THC BioMed's ongoing efforts to expand its product portfolio and meet consumer demand for innovative, high-quality cannabis products. Reported Earnings • Jul 01
Third quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.001 loss in 3Q 2022) Third quarter 2023 results: CA$0.006 loss per share (further deteriorated from CA$0.001 loss in 3Q 2022). Revenue: CA$476.2k (down 32% from 3Q 2022). Net loss: CA$935.2k (loss widened CA$804.1k from 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 06
Second quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.009 loss in 2Q 2022) Second quarter 2023 results: CA$0.006 loss per share (improved from CA$0.009 loss in 2Q 2022). Revenue: CA$817.1k (up 35% from 2Q 2022). Net loss: CA$992.0k (loss narrowed 36% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Board Change • Apr 02
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Penelope Laine was the last director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Reported Earnings • Dec 30
First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0 in 1Q 2022) First quarter 2023 results: CA$0.002 loss per share (further deteriorated from CA$0 in 1Q 2022). Revenue: CA$565.4k (down 32% from 1Q 2022). Net loss: CA$331.5k (down CA$356.5k from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 26
Full year 2022 earnings released: CA$0.019 loss per share (vs CA$0.039 loss in FY 2021) Full year 2022 results: CA$0.019 loss per share (improved from CA$0.039 loss in FY 2021). Revenue: CA$2.45m (down 6.8% from FY 2021). Net loss: CA$3.07m (loss narrowed 52% from FY 2021). Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Reported Earnings • Jul 01
Third quarter 2022 earnings released: CA$0.001 loss per share (vs CA$0.008 loss in 3Q 2021) Third quarter 2022 results: CA$0.001 loss per share (up from CA$0.008 loss in 3Q 2021). Revenue: CA$699.0k (down 37% from 3Q 2021). Net loss: CA$131.1k (loss narrowed 90% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Breakeven Date Change • Apr 27
Forecast to breakeven in 2023 The analyst covering THC Biomed Intl expects the company to break even for the first time. New forecast suggests losses will reduce by 82% to 2022. The company is expected to make a profit of CA$2.12m in 2023. Average annual earnings growth of 164% is required to achieve expected profit on schedule. Reported Earnings • Apr 02
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2022 results: CA$0.009 loss per share (up from CA$0.018 loss in 2Q 2021). Revenue: CA$606.8k (down 41% from 2Q 2021). Net loss: CA$1.55m (loss narrowed 47% from 2Q 2021). Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is forecast to grow 177%, compared to a 130% growth forecast for the industry in Canada. Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings. Announcement • Feb 03
THC BioMed Intl Ltd. Announces Availability of THC KISS Cannabis Biscuits to Consumers Through Ontario Cannabis Store Online and Wholesale to Ontario Retail Stores THC BioMed Intl Ltd. announced that its THC KISS Cannabis Biscuits are now available direct to consumers through Ontario Cannabis Store online and wholesale to Ontario retail stores. Adding to that significant development, the THC KISS Cannabis Biscuits are the lowest priced edibles now available through the Ontario Cannabis Store. This marks the launch of the company's THC KISS brand of full-spectrum cannabis edibles on Ontario Cannabis Store. Ontario Cannabis Store now lists 6 THC BioMed products. THC KISS Cannabis Biscuits are available for $2.95 per pack. Each pack contains 10 mg of THC. Breakeven Date Change • Nov 25
No longer forecast to breakeven The analyst covering THC Biomed Intl no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of CA$1.06b in 2022. New forecast suggests the company will make a loss of CA$825.0k in 2022. Announcement • Sep 25
THC BioMed Intl Ltd. Announces Three New Products to be List and Sold through Ontario Cannabis Stores THC BioMed Intl Ltd. announced that three new the company’s products are to be listed and sold through the Ontario Cannabis Stores: Dragon's Lettuce dried cannabis, THC Kiss Cannabis Biscuits (Cocoa) and THC Kiss Cannabis Biscuits (Cinnamon.) Dragon's Lettuce: the company introduced Dragon's Lettuce into Ontario. It's the company’s most potent sativa landrace strain. It is cultivated indoors in small batches at the company's facility in British Columbia. Dragon's Lettuce has a minimum THC potency of 20%. THC Kiss Cannabis Biscuits – Cocoa and Cinnamon: the company also to begin selling its new offering, THC Kiss Cannabis Biscuits, in Ontario. These edibles come in two delicious flavours: Cocoa and Cinnamon. THC Kiss Biscuits are infused with 10 mg of THC KISS extract, a fast-acting, full-spectrum proprietary cannabis extract invented by the company. All of the company’s products are developed, grown, produced, infused and shipped from its fully integrated facility, in Beautiful British Columbia. Announcement • Sep 01
THC BioMed Announces Shipment of THC KISS Cannabis Biscuits to BC Cannabis Stores THC BioMed Intl Ltd. announced that it has shipped its newly introduced cannabis edible, THC KISS Cannabis Biscuits, to BC Cannabis Stores. The THC KISS Cannabis Biscuits are infused with 10 mg of THC KISS extract, a fast acting, full spectrum proprietary cannabis extract invented by THC BioMed. THC Kiss biscuits come in three delicious varieties: Shortbread, Cocoa and Cinnamon. Announcement • Aug 12
THC Biomed Intl Ltd. announced that it has received CAD 0.5 million in funding THC Biomed Intl Ltd. announced a non-brokered private placement of convertible debentures for gross proceeds of CAD 500,000 on August 10, 2021. The transaction included participation form John Miller, President, CEO and director and Hee Jung Chun. The term of the Debenture is 24 months and bears interest at 10% per annum calculated on an annual basis and payable monthly. The Debenture is convertible into common shares at a price of CAD 0.10 per share, at any time at the election of the company holding the Debenture. In the event that the Company’s common share price on a Canadian stock exchange is CAD 0.60 or greater per common share for a period of 10 or more consecutive trading days, the Company can force the conversion of the entire principal amount plus interest accrued into common shares of the Company at CAD 0.10 per share. Breakeven Date Change • Jul 27
Forecast to breakeven in 2022 The analyst covering THC Biomed Intl expects the company to break even for the first time. New forecast suggests the company will make a profit of CA$1.06b in 2022. Average annual earnings growth of 208% is required to achieve expected profit on schedule. Reported Earnings • Apr 03
Second quarter 2021 earnings released: CA$0.018 loss per share (vs CA$0.001 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: CA$1.02m (down 18% from 2Q 2020). Net loss: CA$2.92m (down CA$3.01m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 50% per year, which means it is significantly lagging earnings. Announcement • Mar 12
THC BioMed Intl Ltd. Ships THC Kiss Gummies to the Province of B.C THC BioMed Intl Ltd. announced that it has shipped its THC Kiss Gummies to B.C. cannabis stores. THC Kiss Gummies are infused with the Company's propriety Kiss cannabis extract. Each package of THC Kiss Gummies contains 4 gummies with a total of 10 mg of THC. Is New 90 Day High Low • Feb 10
New 90-day high: CA$0.26 The company is up 155% from its price of CA$0.10 on 11 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 92% over the same period. Announcement • Jan 29
THC Biomed Intl Ltd. Receives Purchase Order for THC Kiss Gummies from the Province of B.C THC BioMed Intl Ltd. announced that it will begin shipping its THC Kiss Gummies to BC Cannabis Stores. THC is also pleased to advise it has received a reorder for its THC Kiss Gummies from its distributor in Saskatchewan, which has reported brisk sales of THC Kiss Gummies. THC Kiss Gummies are infused with their propriety THC Kiss cannabis extract. Each package of THC Kiss Gummies contains 4 gummies with a total of 10 mg of THC. Reported Earnings • Dec 26
First quarter 2021 earnings released: CA$0.004 loss per share The company reported a poor first quarter result with weaker earnings, revenues and control over expenses. First quarter 2021 results: Revenue: CA$622.0k (down 40% from 1Q 2020). Net loss: CA$692.2k (down 201% from profit in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings. Announcement • Dec 18
THC BioMed Intl Ltd. Launches THC Kiss Gummies in Recreational and Medical Cannabis Markets THC BioMed Intl Ltd. announce that it is now shipping THC Kiss Gummies to the Canadian recreational and medical markets. Shipments are beginning with the province of Saskatchewan, with other provinces to follow. THC Kiss Gummies are infused using proprietary extraction methods invented by THC BioMed. Each THC Kiss Gummy contains 2.5 mg of THC, with each package containing 4 THC Kiss Gummies. Reported Earnings • Nov 15
Full year 2020 earnings released: CA$0.001 loss per share The company reported a solid full year result with reduced losses and improved revenues and control over expenses. Full year 2020 results: Revenue: CA$4.18m (up 181% from FY 2019). Net loss: CA$161.6k (loss narrowed 99% from FY 2019). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings. Announcement • Sep 29
THC Biomed Intl Ltd. Announces Laine Temporarily Resigns as Director of the Company THC BioMed Intl Ltd. announced that Ms. Laine had temporarily resigned as a director of the Company while Health Canada completed a standard security clearance for directors. 
